Market Overview

UPDATE: BMC Initiates Optimer Pharmaceuticals at Buy


BMC is out with its report today on Optimer Pharmaceuticals (NASDAQ: OPTR), initiating OPTR at Buy.

In its report, BMC writes, "We are initiating coverage of Optimer Pharmaceuticals with a Buy Rating and a $20 target price. Our positive opinion is based primarily on the opportunity for the company's newly launched antibiotic, Dificid, to exceed sales expectations in the near and longer term."

Shares of OPTR closed Tuesday at $16.12, up 2.94% from Monday's close.

Posted-In: BMCAnalyst Color Price Target Initiation Analyst Ratings


Related Articles (OPTR)

View Comments and Join the Discussion!

Latest Ratings

HUBBInitiates Coverage On160.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Piper Jaffray Lowers PT on to $41

UPDATE: Jefferies Lowers Price Target on Research in Motion to $21